Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heartcel intramyocardial injection during CABG for ischemic heart disease
2017-000516-42Phase 2Terminated
- Sponsor
- Celixir
- Start
- Jul 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischaemic cardiomyopathy (ICM), coronary arteriosclerosis and myocardial infarction (MI) comparing Heartcel intramyocardial injection during CABG with Placebo intramyocardial injection during CABG (2 arms). Primary endpoint: Change in left ventricular scar volume. Started Jul 2017; status: terminated.
02
Drugs
Heartcel
03
Conditions
ischaemic cardiomyopathy (ICM)coronary arteriosclerosismyocardial infarction (MI)
Beyond the preview
Go deeper on 2017-000516-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000516-42.